- Danaher (DHR) Q2 2026: operating cash flow $1.534B, non‑GAAP free cash flow $1.265B. Life Sciences strongest quarter in years; Diagnostics boosted by respiratory testing components.
- Danaher (DHR) beat quarterly results but cut Q3 core revenue outlook to 2%–3% and trimmed full-year core revenue guidance to 3%–4%; stock fell sharply on the guidance cut.
- Danaher (DHR) saw mid-teens order growth in bioprocessing; revenue hit by ~$100M shipment timing deferral into next year; academic and government demand stabilized.
- Danaher’s Leica Biosystems agreed to buy StatLab, a $250M consumables supplier (85%+ recurring revenue). Deal expected to close by end-2026 and be accretive to adjusted EPS in year one.
TradingView
Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:DHR
- Language
- English
Danaher (DHR) Q2 2026: operating cash flow $1.534B, non‑GAAP free cash flow $1.265B. Life Sciences strongest quarter in years; Diagnostics boosted by respiratory testing components